



AMERICAN SOCIETY OF REGIONAL ANESTHESIA AND PAIN MEDICINE

Practice Advisory on Treatment of Local Anesthetic Systemic Toxicity

For Patients Experiencing Signs or Symptoms of Local Anesthetic Systemic Toxicity (LAST)

- **Get Help**
 - **Initial Focus**
 - *Airway management:* ventilate with 100% oxygen
 - *Seizure suppression:* benzodiazepines are preferred
 - *Basic and Advanced Cardiac Life Support (BLS/ACLS)* may require prolonged effort
 - **Infuse 20% Lipid Emulsion (values in parenthesis are for a 70 kg patient)**
 - *Bolus 1.5 mL/kg* (lean body mass) intravenously over 1 min (~100 mL)
 - *Continuous infusion at 0.25 mL/kg/min* (~18 mL/min; adjust by roller clamp)
 - Repeat bolus once or twice for persistent cardiovascular collapse
 - Double the infusion rate to 0.5 mL/kg per minute if blood pressure remains low
 - *Continue infusion* for at least 10 mins after attaining circulatory stability
 - Recommended upper limit: approximately 10 mL/kg lipid emulsion over the first 30 mins
 - **Avoid** vasopressin, calcium channel blockers, β -blockers, or local anesthetic
 - **Alert** the nearest facility having cardiopulmonary bypass capability
 - **Avoid propofol** in patients having signs of cardiovascular instability
 - **Post LAST events** at www.lipidrescue.org and report use of lipid to www.lipidregistry.org
-

BE PREPARED

- We strongly advise that those using local anesthetics (LAs) in doses sufficient to produce systemic toxicity (LAST) establish a plan for managing this complication. Making a local anesthetic toxicity kit and posting instructions for its use are encouraged.

RISK REDUCTION (BE SENSIBLE)

- Use the least dose of LA necessary to achieve the desired extent and duration of block.
- Local anesthetic blood levels are influenced by site of injection and dose. Factors that can increase the likelihood of LAST include: advanced age, heart failure, ischemic heart disease, conduction abnormalities, metabolic (eg, mitochondrial) disease, liver disease, low plasma protein concentration, metabolic or respiratory acidosis, and medications that inhibit sodium channels. Patients with severe cardiac dysfunction, particularly very low ejection fraction, are more sensitive to LAST and also more prone to receive 'stacked' injections (with resulting elevated LA tissue concentrations) because of slowed circulation time.
- Consider using a pharmacologic marker and/or test dose, for example, epinephrine 5 $\mu\text{g/mL}$ of LA. Know the expected response, onset, duration, and limitations of a "test dose" in identifying intravascular injection.
- Aspirate the syringe prior to each injection while observing for blood.
- Inject incrementally, observing for signs and querying frequently for symptoms of toxicity between each injection.

DETECTION (BE VIGILANT)

- Use standard American Society of Anesthesiologists (ASA) monitors.
- Monitor the patient during and after completing the injection, as clinical toxicity can be delayed up to 30 mins (or longer after tumescent procedures).
- Consider LAST in any patient with altered mental status, neurologic symptoms, or cardiovascular instability following a regional anesthetic.
- Central nervous system signs (may be subtle or absent)
 - Excitation (agitation, confusion, muscle twitching, seizure)
 - Depression (drowsiness, obtundation, coma, apnea)
 - Nonspecific (metallic taste, circumoral numbness, diplopia, tinnitus, dizziness)
- Cardiovascular signs (often the only manifestation of severe LAST)

- Initially may be hyperdynamic (hypertension, tachycardia, ventricular arrhythmias), then
 - Progressive hypotension
 - Conduction block, bradycardia, or asystole
 - Ventricular arrhythmia (ventricular tachycardia, torsades de pointes, ventricular fibrillation)
- Sedative hypnotic drugs reduce seizure risk, but even light sedation may abolish the patient's ability to recognize or report symptoms of rising LA concentrations.

TREATMENT

- Timing of lipid infusion in LAST is controversial. The most conservative approach, waiting until after ACLS has proven unsuccessful, is unreasonable because early treatment can prevent cardiovascular collapse. Infusing lipid at the earliest sign of LAST can result in unnecessary treatment because only a fraction of patients will progress to severe toxicity. The most reasonable approach is to implement lipid therapy on the basis of clinical severity and rate of progression of LAST.
- There is laboratory evidence that epinephrine can impair resuscitation from LAST and reduce the efficacy of lipid rescue. Therefore it is recommended to avoid high doses of epinephrine and use smaller doses, for example, 1 $\mu\text{g/kg}$, for treating hypotension.
- Propofol should not be used when there are signs of cardiovascular instability. Propofol is a cardiovascular depressant with lipid content too low to provide benefit. Its use is discouraged when there is a risk of progression to cardiovascular collapse.
- Prolonged monitoring (≥ 12 hrs) is recommended after any signs of cardiac toxicity because cardiovascular depression due to LAs can persist or recur after treatment.

© 2010 American Society of Regional Anesthesia and Pain Medicine

ASRA hereby grants practitioners the right to reproduce this document as a tool for the care of patients who receive potentially toxic doses of LAs. Publication of these recommendations requires permission from ASRA.

The ASRA Practice Advisory on Local Anesthetic Toxicity is published in the society's official publication *Regional Anesthesia and Pain Medicine*, and can be downloaded from the journal Web site at www.rapm.org.

Neal JM, Weinberg GL, Bernards CM, et al. ASRA practice advisory on local anesthetic systemic toxicity. *Reg Anesth Pain Med* 2010;35:152-161.